Literature DB >> 15954109

Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome.

Jordan J Feld1, Huong Dinh, Tamara Arenovich, Victoria A Marcus, Ian R Wanless, E Jenny Heathcote.   

Abstract

Although the natural history of autoimmune hepatitis (AIH) has been characterized, little is known about patients who present asymptomatically. Consequently, whether they require immunosuppressive therapy with its associated complications is unclear. To compare the natural history of asymptomatic AIH with symptomatic AIH, a large cohort of patients from a single center was examined. All patients with a clinical diagnosis of AIH were reassessed using the revised criteria of the International Autoimmune Hepatitis Group. Liver histology, response to therapy, and survival were assessed. Patients asymptomatic at presentation (n = 31) had lower serum aminotransferase, bilirubin, and immunoglobulin G (IgG) values at baseline. Half of the asymptomatic patients received no therapy, and their survival was no different from that of the total cohort. Ten-year survival was 80.0% (62.5%-97.5%) in the asymptomatic group and 83.8% (75.1%-92.6%) in the symptomatic patients (P = NS). Survival to liver-related endpoints at 10 years was similar in both groups: 89.5% (75.7%-100%) asymptomatic and 83.8% (75.1%-92.6%) symptomatic patients (P = NS). Patients with cirrhosis at baseline had poorer 10-year survival (61.9% [CI 44.9%-78.9%]) than those without cirrhosis at presentation (94.0% [CI 87.4%-100%]) (P = .003) regardless of whether they presented with symptoms or whether they received immunosuppressive therapy. In conclusion, patients with AIH who are asymptomatic at presentation have a good prognosis and may not require immunosuppressive therapy. Cirrhosis on initial liver biopsy portends a poor prognosis in all patients with AIH.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15954109     DOI: 10.1002/hep.20732

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  72 in total

Review 1.  Autoimmune hepatitis: a review.

Authors:  Andrea A Gossard; Keith D Lindor
Journal:  J Gastroenterol       Date:  2012-04-17       Impact factor: 7.527

Review 2.  Advances in the current treatment of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-04-03       Impact factor: 3.199

3.  Autoimmune hepatitis, cirrhosis, and hepatocellular carcinoma (HCC).

Authors:  Palak Jitendrakumar Trivedi; Sue Cullen
Journal:  Dig Dis Sci       Date:  2011-02       Impact factor: 3.199

4.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

Review 5.  Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2017-07-14       Impact factor: 3.199

Review 6.  Juvenile autoimmune hepatitis: Spectrum of the disease.

Authors:  Giuseppe Maggiore; Silvia Nastasio; Marco Sciveres
Journal:  World J Hepatol       Date:  2014-07-27

Review 7.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

Review 8.  Sex-related factors in autoimmune liver diseases.

Authors:  Dorothee Schwinge; Christoph Schramm
Journal:  Semin Immunopathol       Date:  2018-10-01       Impact factor: 9.623

9.  Management of patients with difficult autoimmune hepatitis.

Authors:  Richard Parker; Ye Htun Oo; David H Adams
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

10.  Liver transplantation in adults: Choosing the appropriate timing.

Authors:  Maria Siciliano; Lucia Parlati; Federica Maldarelli; Massimo Rossi; Stefano Ginanni Corradini
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.